Blockade of neurotensin receptors suppresses the dopamine D1/D2 synergism on immediate early gene expression in the rat brain

Eur J Neurosci. 1999 Mar;11(3):967-74. doi: 10.1046/j.1460-9568.1999.00506.x.

Abstract

A remarkable feature of dopamine functioning is that the concomitant activation of D1-like and D2-like receptors acts to intensify the expression of various dopamine-dependent effects, in particular the expression of the immediate-early genes, c-fos and zif268. Using non-peptide neurotensin receptor antagonists, including SR48692, we have determined that blockade of neurotensin receptors reduced the cooperative responses of direct acting D2-like (quinpirole) and partial D1-like (SKF38393) dopamine agonists on the expression of Fos-like antigens and zif268 mRNA. Pretreatment with SR48692 (3 and 10 mg/kg) reduced the number of Fos-like immunoreactive cells produced by the combined administration of SKF38393 (20 mg/kg) and quinpirole (1 mg/kg) in the caudate-putamen, nucleus accumbens, globus pallidus and ventral pallidum. High-affinity neurotensin receptors are likely to be involved in these D1-like/D2-like cooperative responses, as compounds structurally related to SR48692, SR48527 (3 mg/kg) and its (-)antipode, SR49711 (3 mg/kg), exerted a stereospecific antagonism in all selected brain regions. Pretreatment with SR48692 (10 mg/kg) also diminished Fos induction by the indirect dopamine agonist, cocaine (25 mg/kg), particularly at the rostral level of the caudate-putamen. In situ hybridization experiments in the caudate-putamen indicated that SR48692 (10 mg/kg) markedly reduced zif268 mRNA labelling produced by SKF38393 plus quinpirole in cells not expressing enkephalin mRNA, but was unable to affect the concomitant decrease of zif268 mRNA labelling in enkephalin-positive cells. Taken together, the results of the present study indicate that neurotensin is a key element for the occurrence of cooperative responses of D2-like and partial D1-like agonists on immediate-early gene expression.

MeSH terms

  • 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine / pharmacology
  • Animals
  • Brain Chemistry / physiology*
  • Cocaine / pharmacology
  • DNA-Binding Proteins / genetics
  • Dopamine Agonists / pharmacology
  • Dopamine Uptake Inhibitors / pharmacology
  • Early Growth Response Protein 1
  • Enkephalins / analysis
  • Gene Expression / drug effects
  • Gene Expression / physiology
  • Genes, Immediate-Early / physiology*
  • Immediate-Early Proteins*
  • In Situ Hybridization
  • Male
  • Neostriatum / chemistry
  • Neostriatum / cytology
  • Neostriatum / physiology
  • Neurons / chemistry
  • Neurons / drug effects
  • Neurons / physiology
  • Proto-Oncogene Proteins c-fos / genetics
  • Pyrazoles / pharmacology
  • Quinolines / pharmacology
  • Quinpirole / pharmacology
  • RNA, Messenger / analysis
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Dopamine D1 / physiology*
  • Receptors, Dopamine D2 / physiology*
  • Receptors, Neurotensin / antagonists & inhibitors*
  • Transcription Factors / genetics

Substances

  • DNA-Binding Proteins
  • Dopamine Agonists
  • Dopamine Uptake Inhibitors
  • Early Growth Response Protein 1
  • Egr1 protein, rat
  • Enkephalins
  • Immediate-Early Proteins
  • Proto-Oncogene Proteins c-fos
  • Pyrazoles
  • Quinolines
  • RNA, Messenger
  • Receptors, Dopamine D1
  • Receptors, Dopamine D2
  • Receptors, Neurotensin
  • SR 142948
  • SR 48527
  • Transcription Factors
  • SR 48692
  • Quinpirole
  • 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine
  • Cocaine